In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Prof. Michael Hofman from the Peter MacCallum Cancer Centre, Australia, on the results of his study “First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC)”. 

Prof. Hofman discusses the data he presented at ASCO GU24 in San Francisco and suggests that these first-in-human findings with radiolabelled DPI-4452 are encouraging for the subsequent evaluation of treatment with [177Lu]Lu-DPI-4452.

[68Ga]Ga-DPI-4452 provides exceptional images in patients with ccRCC without clinically significant toxicity. Very high SUVs and tumour-to-background ratios suggest potential for use in both diagnostics and patient selection for therapy. The tumour retention and rapid elimination support potential of [177Lu]Lu-DPI-4452 radioligand therapy. 

For more details on this study, you can read the abstract on the UROONCO Kidney Cancer educational platform.